{
    "nct_id": "NCT00254033",
    "title": "The Role of the Dopaminergic Brain Reward System in Apathy Associated With Alzheimer's Disease",
    "status": "COMPLETED",
    "last_update_time": "2017-04-26",
    "description_brief": "Apathy, or lack of motivation, affects up to 80% of Alzheimer's disease (AD) patients. These amotivational symptoms increase patient reliance on caregivers, increase caregiver burden and distress, and increase the risk of patient institutionalization. Only 50% of patients with apathy respond to current treatment with cholinesterase inhibitors. The mechanism of apathy in AD is unknown hampering rational treatment. Our proposed pilot study will provide initial data required to develop an amphetamine challenge paradigm to probe the brain reward system. These results will be used to develop a larger study evaluating the role of the brain reward system in apathy in AD and link this information with pharmacologic treatment. AD is a complex neurobiological illness that needs to be understood at several levels to optimize treatment. At a neurochemical level, one has to identify the neurotransmitter abnormalities that accompany the clinical symptoms. The neurochemical level of analysis provides the link between pathology and symptoms and, for now, is the only avenue for biological therapies. Next, one has to translate knowledge of neurochemical abnormalities to practical treatments for the symptoms of AD. This pilot will allow us to develop a study that can address both of these goals. Furthermore, the larger study will further define the emerging concept of apathy as a syndrome and has broader implications for apathy in many other neuropsychiatric diseases.",
    "description_detailed": "N/A",
    "phase": [
        "PHASE4"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": null,
    "target_category": "neuropsychiatric symptom improvement",
    "drug": [
        "dextroamphetamine (d\u2011amphetamine) \u2014 single 10 mg challenge (used to probe dopaminergic reward system)",
        "methylphenidate \u2014 cited as a dopaminergic treatment studied for apathy in subsequent trials"
    ],
    "placebo": [
        "None (single-dose amphetamine challenge study did not use placebo)",
        "Placebo \u2014 used in later randomized trials of methylphenidate for apathy (e.g., ADMET2)"
    ],
    "explanation_target": [
        "Reason: The study explicitly probes the dopaminergic brain reward system using an amphetamine (dextroamphetamine) challenge to investigate apathy in Alzheimer disease \u2014 a behavioral/neuropsychiatric symptom rather than an attempt to modify core AD pathology. \ue200cite\ue202turn0search1\ue202turn0search0\ue201.",
        "Act (key extracted details): The pilot used a single oral 10 mg dose of dextroamphetamine to assess subjective/behavioral response in AD patients (n\u224820) to probe reward-system function. The project frames this as a way to link reward\u2011system function to pharmacologic treatment of apathy. \ue200cite\ue202turn0search1\ue202turn0search6\ue201.",
        "Act (related pharmacology): Dopaminergic stimulants have been tested as treatments for apathy in AD (small crossover methylphenidate studies and the larger ADMET2 randomized trial), showing methylphenidate can reduce apathy vs placebo \u2014 supporting that the aim is symptom management via dopaminergic modulation. \ue200cite\ue202turn0search4\ue202turn0search3\ue201.",
        "Reflect: Given the intervention (amphetamine challenge) and the stated aim (understand and link reward\u2011system dysfunction to pharmacologic treatment of apathy), the trial targets a neuropsychiatric symptom (apathy). It is not a biologic targeting AD pathology nor a disease\u2011modifying small molecule; nor is it primarily framed as a general cognitive enhancer. The classification as 'neuropsychiatric symptom improvement' therefore best fits. \ue200cite\ue202turn0search2\ue202turn0search5\ue201.",
        "Notes / Ambiguity: The pilot itself is primarily a probe/diagnostic (amphetamine challenge) rather than a therapeutic trial; however its purpose is to inform and predict response to dopaminergic treatments (e.g., methylphenidate). I list both the challenge agent (dextroamphetamine) and the treatment class (methylphenidate) in the drug field and note that placebo was used in later therapeutic trials but not in the single\u2011dose challenge. \ue200cite\ue202turn0search1\ue202turn0search4\ue202turn0search3\ue201"
    ],
    "agent_type": "D) Neurotransmitter Receptors",
    "explanation_agent": [
        "Reason: The intervention probes and modulates the brain's dopaminergic (monoaminergic) reward system using stimulants (dextroamphetamine as a challenge; methylphenidate as a therapeutic class). Both agents act primarily by increasing synaptic dopamine (and norepinephrine) via transporter reversal or blockade (amphetamine-type release and methylphenidate DAT/NET inhibition), so the biological focus is on neurotransmitter signaling rather than core AD pathology. \ue200cite\ue202turn0search6\ue202turn1search0\ue201.",
        "Act: Key extracted details \u2014 dextroamphetamine (single 10 mg challenge) is used to probe dopaminergic reward-system function; methylphenidate (studied therapeutically for apathy in AD) blocks dopamine and norepinephrine transporters and has shown efficacy for apathy in randomized trials (ADMET/ADMET2). These mechanisms place the intervention squarely within modulation of neurotransmitter systems. \ue200cite\ue202turn1search0\ue202turn0search1\ue202turn0search2\ue201.",
        "Reflect: CADRO category D) Neurotransmitter Receptors best fits because the trial's target is the dopaminergic neurotransmitter system (a neurotransmission/modulation mechanism), not an AD disease-modifying target (amyloid, tau, inflammation, etc.). Although the pilot is primarily a pharmacologic probe/diagnostic (which might suggest a non-therapeutic framing), the biological mechanism remains dopaminergic neurotransmission \u2014 therefore D is the appropriate CADRO classification. I considered 'T) Other' because the single-dose challenge is partly diagnostic, but the stated aim to inform dopaminergic treatment for apathy (and the link to methylphenidate therapeutic trials) supports classifying by mechanism rather than by trial intent. \ue200cite\ue202turn0search6\ue202turn1search0\ue202turn0search1\ue201."
    ]
}